Can I read Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test on EtoBox?

Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test by Angela Pista; Nuno Verdasca; Ana Oliveira is a Medicine article available to read on EtoBox.

What is Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test about?

## Abstract Persistent infection by high‐risk human papillomavirus (HR‐HPV) is a cause of cervical cancer. The use of HPV detection in cervical screening programs may improve the ability to identify women at risk of cervical cancer. Therefore, the development of appropriate methods for the detection of HR‐HPV is essential. The aim of this study was to evaluate the clinical performance of the CLART Human Papillomavirus 2 assay (CLART) in comparison with the Hybrid Capture 2 test (HC2), using a clinical cut‐off of cervical intraepithelial neoplasia grade 2 or worse. Discrepant results were analyzed further by the PapilloCheck HPV genotyping system. In the 425 studied women, HR‐HPV positivity rates were similar by both tests (CLART‐13 HR‐HPV: 63.1%; CLART‐17 HR‐HPV: 64.7%; HC2: 64.5%). Agreement between CLART‐13 HR‐HPV (κ = 0.969; concordance level 98.6%), CLART‐17 HR‐HPV (κ = 0.974; concordance level 98.8%), and HC2 were very good. When 13 HR‐HPV types were considered, the two tests showed a clinical sensitivity of 96% (95% CI: 92.6–97.9). The clinical specificity of CLART‐13 HR‐HPV was 73.6% (95% CI: 66.7–79.5) for cervical intraepithelial neoplasia grade 2 or worse, which was compa

Who reads Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test?

Author

Angela Pista; Nuno Verdasca; Ana Oliveira

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley; Research Square (ISSN 0146-6615)

Published

2010

Language

EN

Field

Medicine (Health Sciences)